Biogen (BIIB)
(Delayed Data from NSDQ)
$199.36 USD
-2.08 (-1.03%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $199.26 -0.10 (-0.05%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
BIIB 199.36 -2.08(-1.03%)
Will BIIB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BIIB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BIIB
Eli Lilly Stock Up 21% in 6 Months: Time to Add to Your Portfolio?
Lilly Gets FDA Approval for Eczema Drug Ebglyss
BIIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
Ionis Stock Drops 12% on Pricing of $500M Common Stock Offering
Other News for BIIB
EU pharma committee takes positive view on AbbVie, Merck, others
First Week of November 15th Options Trading For Biogen (BIIB)
Samsung Bioepis, Biogen receive positive CHMP opinion for OPUVIZ
IGM Biosciences: Waiting For Godot
Biogen Inc. (BIIB) Cantor Fitzgerald Global Healthcare Conference (Transcript)